Literature DB >> 27593368

Two cases of malignant lymphoma with reactivation of resolved hepatitis B virus infection after bendamustine hydrochloride monotherapy.

Yoshiki Hiraki1, Akira Kawano, Hirohisa Shigematsu, Koichiro Miki, Hideyuki Nomura, Shinji Shimoda.   

Abstract

A 63-year-old female and a 63-year-old male with resolved HBV infection suffered a relapse of malignant lymphoma. After bendamustine hydrochloride monotherapy, HBV reactivation occurred. Entecavir treatment was commenced immediately, with tests for HBV DNA negative without development of hepatitis. Regular monitoring of HBV DNA based on the guidelines from the Japan Society of Hepatology was useful.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27593368     DOI: 10.11405/nisshoshi.113.1582

Source DB:  PubMed          Journal:  Nihon Shokakibyo Gakkai Zasshi        ISSN: 0446-6586


  1 in total

1.  Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Authors:  Shigeru Kusumoto; Luca Arcaini; Xiaonan Hong; Jie Jin; Won Seog Kim; Yok Lam Kwong; Marion G Peters; Yasuhito Tanaka; Andrew D Zelenetz; Hiroshi Kuriki; Günter Fingerle-Rowson; Tina Nielsen; Eisuke Ueda; Hanna Piper-Lepoutre; Gila Sellam; Kensei Tobinai
Journal:  Blood       Date:  2018-10-19       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.